Curcumin attenuates urinary excretion of albumin in type ii diabetic patients with enhancing nuclear factor erythroid-derived 2-like 2 (Nrf2) system and repressing inflammatory signaling efficacies

Experimental and Clinical Endocrinology and Diabetes

Volumn 123, Issue 6, 2015, Pages 360-367

  Yang, H ^a   Xu, W ^a   Zhou, Z ^a   Liu, J ^b   Li, X ^c   Chen, L ^c   Weng, J ^b   Yu, Z ^a  

^a FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

curcumin; diabetic nephropathy; gut microbiota; lymphocyte; Nrf2

Indexed keywords

ALBUMIN; CASPASE 3; CURCUMIN; I KAPPA B; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TRANSCRIPTION FACTOR NRF2; NFE2L2 PROTEIN, HUMAN; NQO1 PROTEIN, HUMAN;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; DIABETIC NEPHROPATHY; FEMALE; HUMAN; INFLAMMATION; INTESTINE FLORA; LIPID OXIDATION; LIPID PEROXIDATION; LYMPHOCYTE; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; URINARY EXCRETION; URINE LEVEL; ALBUMINURIA; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PATHOLOGY; SIGNAL TRANSDUCTION; URINE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALBUMINURIA; CURCUMIN; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; INFLAMMATION; LIPOPOLYSACCHARIDES; LYMPHOCYTES; MALE; MIDDLE AGED; NAD(P)H DEHYDROGENASE (QUINONE); NF-E2-RELATED FACTOR 2; SIGNAL TRANSDUCTION;

EID: 84930752086     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0035-1545345     Document Type: Article

References (32)

1. Mora-Fernandez C., Dominguez-Pimentel V., de Fuentes M. M. et al. Diabetic kidney disease: from physiology to therapeutics. J Physiol: 2014; 592 3997 4012
2. Arora M. K., Singh U. K. Oxidative stress: meeting multiple targets in pathogenesis of diabetic nephropathy. Curr Drug Targets: 2014; 15 531 538
3. Tan S. M., de Haan J. B. Combating oxidative stress in diabetic complications with Nrf2 activators: how much is too much? Redox Rep: 2014; 19 107 117
4. Impellizzeri D., Esposito E., Attley J. et al. Targeting inflammation: new therapeutic approaches in chronic kidney disease (CKD). Pharmacol Res: 2014; 81 91 102
5. Yu Z., Shao W., Chiang Y. et al. Oltipraz upregulates the nuclear factor (erythroid-derived 2)-like 2 [corrected](NRF2) antioxidant system and prevents insulin resistance and obesity induced by a high-fat diet in C57BL/6J mice. Diabetologia: 2011; 54 922 934
6. Velmurugan G. V., Sundaresan N. R., Gupta M. P. et al. Defective Nrf2-dependent redox signalling contributes to microvascular dysfunction in type 2 diabetes. Cardiovasc Res: 2013; 100 143 150
7. Xu X., Luo P., Wang Y. et al. Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) is a novel therapeutic target for diabetic complications. J Int Med Res: 2013; 41 13 19
8. Tan S. M., Sharma A., Stefanovic N. et al. Derivative of Bardoxolone Methyl, dh404, in an Inverse Dose-Dependent Manner Lessens Diabetes-Associated Atherosclerosis and Improves Diabetic Kidney Disease. Diabetes: 2014; 63 3091 3103
9. Cui W., Bai Y., Miao X. et al. Prevention of diabetic nephropathy by sulforaphane: possible role of Nrf2 upregulation and activation. Oxid Med Cell Longev: 2012; 2012 821936
10. He H. J., Wang G. Y., Gao Y. et al. Curcumin attenuates Nrf2 signaling defect, oxidative stress in muscle and glucose intolerance in high fat diet-fed mice. World J Diabetes: 2012; 3 94 104
11. Khajehdehi P., Pakfetrat M., Javidnia K. et al. Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-beta and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study. Scand J Urol Nephrol: 2011; 45 365 370
12. Soetikno V., Suzuki K., Veeraveedu P. T. et al. Molecular understanding of curcumin in diabetic nephropathy. Drug Discov Today: 2013; 18 756 763
13. Gupta S. C., Patchva S., Aggarwal B. B. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J: 2013; 15 195 218
14. Meng B., Li J., Cao H. Antioxidant and antiinflammatory activities of curcumin on diabetes mellitus and its complications. Curr Pharm Des: 2013; 19 2101 2113
15. Weisberg S. P., Leibel R., Tortoriello D. V. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology: 2008; 149 3549 3558
16. Roshan B., Stanton R. C. A story of microalbuminuria and diabetic nephropathy. J Nephropathol: 2013; 2 234 240
17. Dall T. M., Narayan K. M., Gillespie K. B. et al. Detecting type 2 diabetes and prediabetes among asymptomatic adults in the United States: modeling American Diabetes Association versus US Preventive Services Task Force diabetes screening guidelines. Popul Health Metr: 2014; 12 12
18. Yu Z., Morrison M. Improved extraction of PCR-quality community DNA from digesta and fecal samples. Biotechniques: 2004; 36 808 812
19. Suresh B. P., Srinivasan K. Amelioration of renal lesions associated with diabetes by dietary curcumin in streptozotocin diabetic rats. Mol Cell Biochem: 1998; 181 87 96
20. Srinivasan M. Effect of curcumin on blood sugar as seen in a diabetic subject. Indian J Med Sci: 1972; 26 269 270
21. Chuengsamarn S., Rattanamongkolgul S., Phonrat B. et al. Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial. J Nutr Biochem: 2014; 25 144 150
22. Soetikno V., Suzuki K., Veeraveedu P. T. et al. Molecular understanding of curcumin in diabetic nephropathy. Drug Discov Today: 2013; 18 756 763
23. Badal S. S., Danesh FR. New insights into molecular mechanisms of diabetic kidney disease. Am J Kidney Dis: 2014; 63 S63 S83
24. Nymark M., Pussinen P. J., Tuomainen A. M. et al. Serum lipopolysaccharide activity is associated with the progression of kidney disease in finnish patients with type 1 diabetes. Diabetes Care: 2009; 32 1689 1693
25. Bereswill S., Munoz M., Fischer A. et al. Anti-inflammatory effects of resveratrol, curcumin and simvastatin in acute small intestinal inflammation. PLoS One: 2010; 5 e15099
26. Cox A. J., West N. P., Cripps AW. Obesity, inflammation, and the gut microbiota. Lancet Diabetes Endocrinol: 2014; 5 437 445
27. Khan M. T., Nieuwdorp M., Backhed F. Microbial Modulation of Insulin Sensitivity. Cell Metab: 2014; 20 753 760
28. Stenman L. K., Waget A. Garret C, Klopp P, Burcelin R, Lahtinen S. Potential probiotic Bifidobacterium animalis ssp. lactis 420 prevents weight gain and glucose intolerance in diet-induced obese mice. Benef Microbes: 2014; 5 437 445
29. Zhang Y., Guo X., Guo J. et al. Lactobacillus casei reduces susceptibility to type 2 diabetes via microbiota-mediated body chloride ion influx. Sci Rep: 2014; 4 5654
30. Gomes A. C., Bueno A. A. de Souza RG, Mota JF. Gut microbiota, probiotics and diabetes. Nutr J: 2014; 13 60
31. Ma J., Chadban S. J., Zhao C. Y. et al. TLR4 activation promotes podocyte injury and interstitial fibrosis in diabetic nephropathy. PLoS One: 2014; 9 e97985
32. Yang M., Gan H., Shen Q. et al. Proinflammatory CD14+CD16+ monocytes are associated with microinflammation in patients with type 2 diabetes mellitus and diabetic nephropathy uremia. Inflammation: 2012; 35 388 396